Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) Institutional Ownership
CUSIP: 152309100
13F Institutional Holders and Ownership History from Q2 2021 to Q1 2026
Institutions Reporting
147
Shares (Excl. Options)
143,761,351
Price
$25.01
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Ordinary shares, nominal value 0.002 GBP per share
- Symbol
- CNTA on Nasdaq
- Shares outstanding
- 145,993,531
- Price per share
- $39.72
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 143,761,351
- Total reported value
- $3,595,359,236
- % of total 13F portfolios
- 0.01%
- Share change
- +15,436,787
- Value change
- +$388,868,676
- Number of holders
- 147
- Price from insider filings
- $39.72
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- CNTA - Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share is tracked under CUSIP 152309100.
- 147 institutions reported positions in Q4 2025.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 147 to 8 between Q4 2025 and Q1 2026.
- Reported value moved from $3,595,359,236 to $484,568.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 147 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 152309100?
CUSIP 152309100 identifies CNTA - Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 152309100:
Significant Owners of Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 10% | +24% | $364,034,431 | +$93,724,350 | 14,555,555 | +35% | Avoro Capital Advisors LLC | 31 Dec 2025 |
| FMR LLC | 12% | +23% | $275,104,823 | +$52,642,399 | 10,999,793 | +24% | FMR LLC | 30 Jan 2026 |
| Adage Capital Management, L.P. | 7.5% | +20% | $243,348,750 | +$39,576,000 | 10,035,000 | +19% | Adage Capital Management, L.P. | 30 Sep 2025 |
| General Atlantic Cooperatief U.A. | 5% | -23% | $180,192,368 | -$56,624,900 | 7,366,818 | -24% | General Atlantic Cooperatief U.A. | 25 Nov 2025 |
As of 31 Dec 2025, 147 institutional investors reported holding 143,761,351 shares of Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA). This represents 98% of the company’s total 145,993,531 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) together control 82% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 14% | 19,963,157 | 0% | 60% | $499,278,557 |
| Avoro Capital Advisors LLC | 10% | 14,555,555 | +35% | 3.6% | $364,034,431 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 7.7% | 11,281,741 | +12% | 0.43% | $282,156,342 |
| Index Venture Life Associates VI Ltd | 6.8% | 9,961,789 | 0% | 100% | $249,144,343 |
| FMR LLC | 6.1% | 8,961,939 | +43% | 0.01% | $224,138,094 |
| GENERAL ATLANTIC, L.P. | 4.2% | 6,117,715 | -37% | 5.3% | $153,004,052 |
| FARALLON CAPITAL MANAGEMENT LLC | 3.7% | 5,377,068 | +24% | 0.78% | $134,480,471 |
| TCG Crossover Management, LLC | 2.9% | 4,286,480 | +37% | 3.5% | $107,204,865 |
| JANUS HENDERSON GROUP PLC | 2.8% | 4,093,608 | -24% | 0.05% | $102,393,318 |
| Siren, L.L.C. | 2.8% | 4,027,517 | +25% | 3% | $100,728,200 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.7% | 3,927,343 | -18% | 0.01% | $98,223,000 |
| EcoR1 Capital, LLC | 2.1% | 3,115,000 | +466% | 3.6% | $77,906,150 |
| PERCEPTIVE ADVISORS LLC | 2% | 2,917,634 | -5.9% | 1.3% | $72,970,026 |
| FRANKLIN RESOURCES INC | 1.6% | 2,368,381 | -7.4% | 0.01% | $59,233,201 |
| FEDERATED HERMES, INC. | 1.6% | 2,342,139 | +34% | 0.1% | $58,576,896 |
| First Light Asset Management, LLC | 1.6% | 2,278,940 | -37% | 4.4% | $56,996,289 |
| BRAIDWELL LP | 1.5% | 2,188,320 | 1.8% | $54,729,883 | |
| Deep Track Capital, LP | 1.4% | 2,000,000 | 1.1% | $50,020,000 | |
| MILLENNIUM MANAGEMENT LLC | 1.3% | 1,870,671 | +107% | 0.03% | $46,785,482 |
| RTW INVESTMENTS, LP | 1.2% | 1,790,837 | -22% | 0.45% | $44,788,833 |
| MAVERICK CAPITAL LTD | 1.1% | 1,643,724 | 0.44% | $41,109,537 | |
| Foresite Capital Management VI LLC | 0.93% | 1,364,019 | +3.8% | 10% | $34,114,115 |
| Cormorant Asset Management, LP | 0.91% | 1,325,000 | -31% | 1.9% | $33,138,250 |
| Capital World Investors | 0.79% | 1,158,699 | +69% | 0% | $28,979,062 |
| STEMPOINT CAPITAL LP | 0.79% | 1,154,114 | +76% | 5% | $28,864,391 |
Institutional Holders of Centessa Pharmaceuticals plc - Ordinary shares, nominal value 0.002 GBP per share (CNTA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 12,209 | $484,568 | -$10,784,073 | $39.72 | 8 |
| 2025 Q4 | 143,761,351 | $3,595,359,236 | +$388,868,676 | $25.01 | 147 |
| 2025 Q3 | 128,332,503 | $3,111,987,564 | +$147,803,679 | $24.25 | 124 |
| 2025 Q2 | 123,569,478 | $1,623,678,828 | -$30,690,539 | $13.14 | 117 |
| 2025 Q1 | 124,913,742 | $1,797,461,231 | -$6,439,160 | $14.38 | 130 |
| 2024 Q4 | 124,413,136 | $2,083,915,345 | +$72,898,202 | $16.75 | 114 |
| 2024 Q3 | 108,571,980 | $1,737,489,847 | +$315,516,266 | $15.99 | 101 |
| 2024 Q2 | 86,506,981 | $781,158,600 | +$108,671,569 | $9.03 | 79 |
| 2024 Q1 | 74,395,267 | $840,663,455 | +$66,659,727 | $11.30 | 69 |
| 2023 Q4 | 71,279,084 | $567,382,245 | +$15,317,885 | $7.96 | 56 |
| 2023 Q3 | 72,578,425 | $469,582,127 | +$14,480,766 | $6.47 | 46 |
| 2023 Q2 | 70,339,619 | $435,403,089 | +$25,413,534 | $6.19 | 43 |
| 2023 Q1 | 66,895,058 | $257,540,618 | +$13,125,714 | $3.85 | 42 |
| 2022 Q4 | 62,684,642 | $194,353,719 | +$5,918,047 | $3.10 | 41 |
| 2022 Q3 | 71,808,783 | $288,649,039 | -$842,289 | $4.02 | 41 |
| 2022 Q2 | 71,775,040 | $349,577,531 | -$37,633,222 | $4.87 | 40 |
| 2022 Q1 | 74,581,035 | $669,057,512 | +$23,146,015 | $8.97 | 40 |
| 2021 Q4 | 71,873,880 | $807,766,000 | +$18,577,946 | $11.26 | 46 |
| 2021 Q3 | 52,983,439 | $881,813,000 | +$147,088,157 | $16.70 | 38 |
| 2021 Q2 | 47,409,892 | $1,045,414,000 | +$1,045,413,999 | $22.21 | 49 |